TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02684448

Intervention type: PROCEDURE
Intervention: Inguinal Hernia Repair
Description: Inguinal (unilateral or bilateral) hernia repair

Intervention type: PROCEDURE
Intervention: Inguinal Hernia Repair
Description: Inguinal (unilateral or bilateral) hernia repair
Study: NCT01875159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 6 mg/kg/day
Description: Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
Study: NCT03779542

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: phacoemulsification and intraocular lens implantation

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: phacoemulsification and intraocular lens implantation
Study: NCT01538069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP group
Description: The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and CPAP group
Description: The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
Study: NCT03462108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus (Bio Farma) Vaccine
Description: Rotavirus (Bio Farma) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus (Bio Farma) Vaccine
Description: Rotavirus (Bio Farma) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus (Bio Farma) Vaccine
Description: Rotavirus (Bio Farma) Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains 30% sucrose in DMEM
Study: NCT02921672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
Study: NCT01389882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neurally adjusted ventilatory assist (NAVA) ventilator mode
Description: Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
Study: NCT04589858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise protocol
Description: Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise protocol
Description: Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specified Manual Therapies
Description: Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position.
Study: NCT00436995

Intervention type: DRUG
Group type: OTHER
Intervention: Darbepoetin Alfa
Description: Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
Study: NCT02539797

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: comparing anodal, cathodal, and sham tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: comparing anodal, cathodal, and sham tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: comparing anodal, cathodal, and sham tDCS
Study: NCT02762695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management
Description: A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care at Primary Health Care Center
Study: NCT05721495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: freeze all strategy embryo transfer
Description: criopreservation of all viable embryos in order to transfere the best one in a posterior cycle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fresh embryo transfer strategy
Description: transfer of the best embryo two or three days after the fecundation technique
Study: NCT03958175

Intervention type: OTHER
Intervention: Alouette test (reading test)
Description: The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.

Intervention type: OTHER
Intervention: Alouette test (reading test)
Description: The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
Study: NCT03430791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg IV
Description: Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg IV
Description: Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg
Description: Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg
Description: Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF200A (Optune)
Description: A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF200A (Optune)
Description: A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.
Study: NCT02016976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Analgesic Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dormicum 2.5 mg and Pethidine 25 mg
Description: Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
Study: NCT02937337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion with videostylet guided technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion with standard blind technique
Study: NCT01390896

Intervention type: DRUG
Intervention: Fondaparinux Sodium
Study: NCT01909895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anger Induction
Description: The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depressed Mood Induction
Description: The participant will be asked to undergo a validated depression/sadness induction task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Induction
Description: The participant will be asked to undergo a validated anxiety induction task.

Intervention type: OTHER
Group type: OTHER
Intervention: Neutral emotion task
Description: This is a neutral control task that each of the negation emotion induction tasks will be compared to.
Study: NCT01493193

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training with constant work load
Description: Endurance training with constant work load(n=15): 31min at 65-75% HRmax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyramid-Training
Description: Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
Study: NCT00633971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex lymphedema therapy
Description: Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: complex lymphedema therapy
Description: Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
Study: NCT04543773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.
Study: NCT02981368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: PET/CT imaging will be acquired 1-2 hours post-PyL injection
Study: NCT04360746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical intervention
Description: Pharmaceutical intervention will include a complete medication review by a clinical pharmacist with the following process: medication reconciliation, medication indication and dosage check, medication effectiveness and appropriateness assessment, drug-drug or drug-disease interactions check, medication duplications check, length and cost of treatment evaluation. The pharmacist will use the following tools: Medication appropriateness index (MAI), ACB (Anticholinergic cognitive burden) score and the using the assessment of underutilization (AOU) index.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.
Study: NCT03902691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegol-Sihematide
Description: Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESPO
Description: Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
Study: NCT04510649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A
Description: in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B
Description: in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
Study: NCT03689582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Positron Emission Tomography/Computed Tomography (PET/CT) imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi).
Study: NCT00855959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Turbuhaler
Description: Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
Study: NCT00003575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study: NCT03999515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study: NCT01742195

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oral EBUS insertion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal EBUS insertion
Study: NCT02166099

Intervention type: PROCEDURE
Intervention: Choledochoscopy using Digital Spyglass
Description: Choledochoscopy using Digital Spyglass during Endoscopy
Study: NCT00799682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: 0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan Z
Description: 0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
Study: NCT01419795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00769886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen/naphazoline
Description: One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen
Description: One drop of Ketotifen in study eye at visit 3 and visit 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naphazoline
Description: One drop of naphazoline in study eye at vist 3 and visit 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop of vehicle in study eye at visit 3 and visit 4.
Study: NCT00060645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
Study: NCT01790594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte Globulin (Rabbit)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte Globulin (Rabbit)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: There may be an opportunity to withdraw tacrolimus at week 40

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: There may be an opportunity to withdraw tacrolimus at week 40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Study: NCT02155634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.